"Starpharma has signed a memorandum of understanding with a Chinese company to make and sell its VivaGel-coated condom in China...The Chinese company is a major supplier of condoms to the Chinese government's Birth Control Department and Disease Prevention Department. The so-called government market in China requires about three billion condoms each year for birth control and disease prevention."

Go to the article (external link)

Starpharma is pleased to attach documentation regarding its Share Purchase Plan (SPP).

Starpharma announced today that it has signed a Memorandum of Understanding (MOU) with a Chinese company who is a major provider of condoms to the Chinese government.  The MOU outlines the key commercial and other terms for Starpharma’s partner to manufacture and sell a VivaGel^® coated condom to the Government segment of the Chinese market.

Starpharma is pleased to announce it has raised A$32 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which will raise up to a further A$3 million.

Starpharma today announced that AstraZeneca has selected a second DEP™ candidate and Starpharma will now commence a new DEP™ project incorporating the second proprietary AstraZeneca oncology molecule.